EQS-Adhoc: Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights 02-Sep-2024 / 17:46 CET/CEST Disclosure of an…